Download MendeleyAzatricyclic Inverse Agonists of ROR gamma t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.
Liu, Q., Xiao, H.Y., Batt, D.G., Xiao, Z., Zhu, Y., Yang, M.G., Li, N., Yip, S., Li, P., Sun, D., Wu, D.R., Ruzanov, M., Sack, J.S., Weigelt, C.A., Wang, J., Li, S., Shuster, D.J., Xie, J.H., Song, Y., Sherry, T., Obermeier, M.T., Fura, A., Stefanski, K., Cornelius, G., Chacko, S., Khandelwal, P., Dudhgaonkar, S., Rudra, A., Nagar, J., Murali, V., Govindarajan, A., Denton, R., Zhao, Q., Meanwell, N.A., Borzilleri, R., Dhar, T.G.M.(2021) ACS Med Chem Lett 12: 827-835
- PubMed: 34055233
- DOI: https://doi.org/10.1021/acsmedchemlett.1c00112
- Primary Citation of Related Structures:
7LUK - PubMed Abstract:
Structure-activity relationship studies directed toward the replacement of the fused phenyl ring of the lead hexahydrobenzoindole RORγt inverse agonist series represented by 1 with heterocyclic moieties led to the identification of three novel aza analogs 5 - 7 . The hexahydropyrrolo[3,2- f ]quinoline series 5 (X = N, Y = Z=CH) showed potency and metabolic stability comparable to series 1 but with improved in vitro membrane permeability and serum free fraction. This structural modification was applied to the hexahydrocyclopentanaphthalene series 3 , culminating in the discovery of 8e as a potent and selective RORγt inverse agonist with an excellent in vitro profile, good pharmacokinetic properties, and biologic-like in vivo efficacy in preclinical models of rheumatoid arthritis and psoriasis.
Organizational Affiliation:
Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
